On September 18th, 2013, Clarkston co-sponsored and attended Pennsylvania Bio’s Leadership Panel Program’s Fall CEO Roundtable, which brought together executives, ...

The road to market for a novel biotech therapy is among the most expensive, demanding courses for entrepreneurs to undertake, ...

Pharmaceutical giant GSK recently announced the formation of a $50 million venture capital fund, Action Potential Venture Capital (APVC) Limited, ...

Fortune 500 CEO Indra Nooyi recently provided her perspectives on sustainable capitalism at the ICGN Annual Conference in New York ...

The economics of pay-for-delay agreements are clear – branded drug makers benefit from an extended amount of time on the ...

As if serialization efforts aren’t complicated enough working within our own manufacturing organizations, syncing our efforts with our trading partners ...

Clarkston, along with 20,000 others in the SAP community, descended on Orlando, Florida last week for SAP’s SAPPHIRE Now + ...

Combination drugs continue to grow in popularity as novel alternatives and advances in biotechnology, pharmaceuticals and medical devices.  The market ...

A basic fact of life is that the things in this world we want more of – time, money, resources ...

Austere times in Europe continue to challenge local governments to reduce healthcare spend. Leveraging Europe’s reference pricing policies, Eurozone countries ...

In this 2013 Life Sciences Trends Report, we understand it is important to know who you are, define the strategy, ...

Recent hype about John Mackey’s “Conscious Capitalism” has drawn attention to the business shift from shareholder to stakeholder value. Increasingly, ...